Lupus Foundation of America4d
Fate Therapeutics Announces Promising Initial Data from FT819 Phase 1 Study for Moderate to Severe Systemic Lupus Erythematosus
Fate Therapeutics has announced encouraging initial data from the FT819 phase 1 autoimmunity study for people with ...
Yahoo Finance4d
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?
Its immuno-oncology pipeline includes iPSC-derived natural killer (NK) cells and T-cell product candidates. A phase I study of FT819, a T-cell product candidate for patients with systemic lupus ...
Hold Rating for Fate Therapeutics Amid Incremental Progress in CD19 CAR-T Therapy Development
Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Hold rating on Fate Therapeutics (FATE – Research Report). The ...